Interviews

A recent study reveals cognitive behavioral therapy significantly enhances lung cancer patients' ability to manage dyspnea and anxiety, improving overall quality of life.

Dr. Christian S. Hinrichs discusses the future of specialized cell therapies, predicting broader access for community clinics similar to CAR T cell treatments.

Dr. Hinrichs emphasizes the critical need for early referrals and screenings for patients considering advanced cell therapies, enhancing treatment outcomes.

Dr. Christian S. Hinrichs discusses promising results from a phase 2 study on engineered TCR-T cell therapy for HPV-associated cancers.

Hinrichs discusses groundbreaking findings on TIL therapy for HPV-related cancers, highlighting long-term disease-free outcomes in patients.

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, transforming treatment options for patients.

Highlands Oncology's innovative remote monitoring model enhances cancer care, reducing ED visits and improving treatment adherence through effective symptom management.

Che-Kai Tsao, MD, MS, discusses the current state of treatment for metastatic hormone-sensitive prostate cancer.

A novel immune-based therapy shows 100% response rates in newly diagnosed multiple myeloma patients, highlighting its potential as a frontline treatment.

Experts discuss the evolving strategies in managing immune-related adverse events in cancer treatment, emphasizing precision immunomedicine and patient history.

Frederick L. Locke, MD, discusses the 2025 removal of the REMS program for CAR T-cell therapy and the resulting improvements to patient access.

Discover evolving strategies for managing immune-related adverse events in cancer immunotherapy, enhancing decision-making for oncologists and practitioners.

Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues and achalasia in patients.

Dr. Michael Soulen discusses safety concerns and adverse events in neuroendocrine tumor treatments, highlighting cytopenia and radiation risks while ensuring patient safety.

Chandler H. Park, MD, discusses real-world data for maintenance avelumab in bladder cancer and factors that sway his treatment selection.

Jason S. Starr, DO, discusses the significance of the extrapancreatic neuroendocrine tumor cohort of the phase 3 CABINET trial of cabozantinib.

A novel treatment combining chemotherapy and PRRT shows promising safety and efficacy for neuroendocrine tumors, with high response rates and ongoing trials.

Experts explore a novel combined therapy for liver-dominant neuroendocrine tumors, enhancing treatment durability with chemotherapy and PRRT.

Dr. Jonathan Strosberg discusses the promising results of the ALPHAMEDIX-02 trial, evaluating a new therapy for advanced neuroendocrine tumors.

Vivek Subbiah emphasizes tumor-agnostic therapies' potential to revolutionize cancer treatment by targeting genetic biomarkers, ensuring equitable access to precision medicine.

Experts discuss the importance of collaboration in improving surgical standards and treatment outcomes for neuroendocrine tumors through the CUTNETs initiative.

Healthcare professionals adjust octreotide and lanreotide doses for effective symptom control in patients with carcinoid syndrome, following NCCN guidelines.

Mary Maluccio, MD, MPH, FACS, discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 trial and ongoing patient follow-up.

Dr Mary Maluccio discusses promising results and safety concerns from the ALPHAMEDIX-02 trial on innovative therapy for GEP-NETs.

New trial results reveal ITM-11 significantly improves survival rates in GEP-NET patients, outperforming everolimus with better efficacy and safety profiles.

A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell carcinoma, despite higher toxicity risks.

A new study reveals that combining TAR-200 with cetrelimab significantly improves treatment outcomes for muscle-invasive bladder cancer patients.

Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns and the need for further research.

Explore the latest insights on somatostatin analogs, dose adjustments, and emerging treatments for managing carcinoid syndrome symptoms effectively.

Experts discuss the CUTNETs collaborative's efforts to enhance surgical care and standardize treatment for neuroendocrine tumors across multiple centers.